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ABSTRACT
Objectives: We aimed to design and test a method to
extract information on antithrombotic therapy from
anonymised free-text notes in the Clinical Practice
Research Datalink (CPRD).
Setting: General practice database representative of
the UK.
Participants: All patients undergoing total hip
replacement (THR, n=25 898) or total knee
replacement (TKR, n=22 231) between January 2008
and October 2012 were included. Antithrombotic drug
use related to THR or TKR was identified using
anonymised free text and prescription data.
Primary and secondary outcome measures:
Internal validity of our newly designed method was
determined by calculating positive predictive values
(PPVs) of hits for predefined keywords in a random
sample of anonymised free-text notes. In order to
determine potential detection bias, total joint
replacement (TJR) patient characteristics were
compared as per their status of exposure to
antithrombotics.
Results: PPVs ranging between 97% and 99% for
new oral anticoagulants (NOAC) or low-molecular
weight heparins (LMWH) exposure related to TJR were
obtained with our method. Our search strategy
increased detection rates by 57%, yielding a total
proportion of 18.5% of all THR and 18.6% of all TKR
surgeries. Identified users of NOACs and LMWHs were
largely similar with regards to age, sex, lifestyle,
disease and drug history compared to patients without
identified drug use.
Conclusions: We have developed a useful method to
identify additional exposure to NOACs or LMWHs with
TJR surgery.
INTRODUCTION
Osteoarthritis (OA) is the most common
musculoskeletal condition in older people in
the UK.1 Based on 7-year consultation preva-
lence in British general practice, an esti-
mated 8.75 million people have been treated
for OA. This constitutes one-third people
aged 45 years and over in the UK.1 Total
joint replacements (TJR), such as total hip
replacement (THR) or total knee replace-
ment (TKR), substantially improve quality of
life in these patients.2 However, risk of poten-
tially fatal venous thromboembolic events,
such as deep-vein thrombosis (DVT), is
increased up to 14-fold following these
surgical procedures when no drug for throm-
boprophylaxis is given.3 Intensive antithrom-
botic treatment up to 35 days is, therefore,
recommended and has resulted in a reduced
risk of asymptomatic DVT in a meta-analysis
of randomised trails (RR=0.51, 95% CI (0.45
to 0.59), p<0.001).4 5
There has been much debate about the
risk/beneﬁt ratio of antithrombotic agents
following THR or TKR surgery.6–8
Low-molecular weight heparins (LMWHs)
have gained popularity in the past decade,
but can only be administered subcutaneously.
The recently introduced orally administered
direct thrombin inhibitors and direct
factor Xa inhibitors (eg, dabigatran and
Strengths and limitations of this study
▪ This is the first study reporting an effective
method to identify antithrombotic drug use in
anonymised free text in a large population-based
database.
▪ Our method can be implemented at relatively low
costs.
▪ We were unable to determine the specificity and
sensitivity of our method.
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rivaroxaban) seem to combine both advantages of
vitamin-K antagonists (VKAs) and LMWHs. Their
beneﬁt-risk proﬁle has been suggested to outperform
VKAs in patients with atrial ﬁbrillation.9 To further
understand the beneﬁt/risk proﬁle of these antithrom-
botic drugs in real life use, data form large databases,
such as the Clinical Practice Research Datalink (CPRD),
could contribute largely . However, some antithrombotic
therapy are ‘red-listed’ and therefore, predominantly dis-
pensed during inpatient hospitalisations and the period
postdischarge. Consequently, patients do not have to
visit a public pharmacy to repeat their prescription.
Unfortunately, inhospital pharmacy data is often lacking
in general practitioner (GP) databases. Therefore, there
are limitations in using these databases to conduct drug
utilisation or drug effect studies. However, Martinez
et al10 have found a feasible approach to overcome some
of these restrictions. They identiﬁed a total of 754 rivar-
oxaban users by combining information from prescrip-
tion ﬁles and electronic search of anonymised free text
in the CPRD between October 2008 and January 2012.
Approximately 66% of these users were identiﬁed by
anonymised free text only, thereby tripling the informa-
tion on exposure to rivaroxaban. Unfortunately, details
of the electronic search method used were lacking in
this study and it focused only on one drug
(rivaroxaban).
In order to assess safety and efﬁcacy of the new oral
anticoagulants (NOACs), new methods are needed to
efﬁciently extract the additional information from anon-
ymised free-text notes. In some ﬁelds this has already
been done. For example, Shah designed an algorithm
that identiﬁes dosage instructions for a variety of drugs
in anonymised free text. Their algorithm converted
unstructured data from these notes to structured, usable
data. They subsequently validated their structured data
by manually checking a random sample of these
records. Their algorithm identiﬁed correct dosage infor-
mation in 99% of the analysed anonymised free text.11
Since inhospital pharmacy data are not included in most
primary care databases, we aimed to design and test a
method to extract additional information on antithrom-
botic therapy in patients undergoing TJR surgery from
anonymised free-text notes in the CPRD.
METHODS
Data source
This study was conducted using CPRD GOLD, formally
known as the General Practice Research Database
(GPRD). The CPRD is a GP database currently contain-
ing approximately 8% of the UK population. GPs play a
key role in the UK healthcare system, as they are respon-
sible for primary healthcare and specialist referrals.
Consequently, medical information from GPs, specialist
referrals and hospitalisation data are recorded in the
CPRD.12 Most data are recorded using CPRD’s therapy
ﬁles, but some data, such as hospital discharge
summaries, are collected as anonymised free text. CPRD
has been used to study outcomes after TJR surgery.13 14
Study population
The study population comprised all patients who under-
went a primary THR or TKR surgery from January 2008
to October 2012. This time frame was chosen because
NOACs have been registered for antithrombotic therapy
after TKR and THR in Europe since 2008 (dabigatran,
18 March 2008; rivaroxaban, 13 September 2008).
Selection of comparison groups
We determined the exposure to antithrombotics using
CPRD product codes and analysis of anonymised free
text. Use of product codes of NOACs (dabigatran and
rivaroxaban), LMWHs (bemiparin, certoparin, reviparin,
enoxaparin, tinzaparin, dalteparin), and aspirin during
the 10 days before and 10 days after surgery were
included. Based on the annual reports of the National
Joint Registry (NJR), VKAs were used for thrombopro-
phylaxis in <1% of the TJR surgeries. They were, there-
fore, not included in the analyses. The procedure of the
anonymised free-text analysis (ﬁgure 1) was based on
methods used in a previous study that identiﬁed rivarox-
aban use and a study that restructured dosage instruc-
tions.10 11 For the anonymised free-text analysis, we ﬁrst
ran our search strategy on the study population to deter-
mine the use of NOACs, LMWHs and aspirin. This
search strategy searched for speciﬁc keywords in the
anonymised free-text notes of TJR patients. Keywords
included abbreviations, mis-spelled variations, and actual
names of both the generic and the brand products (see
online supplementary appendix table S1). Anonymised
free-text notes between 10 days before and 10 days after
date of surgery were included in the analysis. This time
window was based on the mean duration of hospital
stays after TJRs, as reported in the National Registry of
Hospitalisations of England (2008–2013). 15
Patients with a positive hit for these keywords were
further analysed to determine the validity of this positive
response. From both THR and TKR patients, we ran-
domly selected 100 patients with at least one positive
NOAC hit, 100 patients with at least one positive LMWH
hit and 100 patients with at least one positive aspirin hit.
This resulted in a total of 300 THR patients and 300
TKR patients. Additionally, anonymised free-text notes
of these randomly selected patients were analysed. The
additional analysis consisted of anonymising of the free-
text surrounding the positive hit in each record. By
anonymising 20 words before and after the positive hit,
we either conﬁrmed or refuted the drug use. In the fol-
lowing examples drug use was conﬁrmed (1) or refuted
(2), respectively:
1. …still on dabigatran…
2. …aspirin was stopped in …
Within the anonymised free text, we manually
searched for negating or conﬁrming terms. Two phar-
macists ( JTHN and FdV) then independently decided
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whether a patient had been exposed or unexposed to
antithrombotic drugs. In case of disagreement, the par-
ticipant was discussed until an agreement was reached.
Subsequantly we determined exposure to antithrom-
botics in the entire study population by combining drug
use based on a positive response in the anonymised free-
text analysis and drug use based on product codes (see
online supplementary appendix table S2). Concomitant
use of NOACs and aspirin were categorised as NOAC
use. Concomitant use of LMWHs and aspirin were cate-
gorised as LMWH use. This classiﬁcation was chosen
because it is more likely that in these cases the exposure
to NOACs or LMWHs is associated with TJR. Patients
without identiﬁed drug use were categorised as
unknown users. Exposure to a NOAC and a LMWH is
highly unlikely. Therefore, concomitant use of these
drugs was also classiﬁed as unknown use.
Data analysis
Positive predictive values (PPVs) of the positive hits by
free-text search were calculated by dividing the number
of positive hits, conﬁrmed by manual analysis of sur-
rounding free text, by the total number of positive hits.
PPVs can range between 0% and 100%, where 100%
corresponds with perfect predictive value of positive hits.
We were unable to calculate false or true negatives
because we did not analyse the free-text notes without a
positive hit. As a result, we could not determine the spe-
ciﬁcity and sensitivity of our method. In order to assess
the additional detection rate by using our free-text
search, we determined the distribution of cases within a
drug category according to the identiﬁcation method.
Cases were categorised according to type of surgery and
the previously described user categories. To gain insight
for the external validity of the method, we ﬁrst com-
pared the proportion of NOAC and LMWH use in the
CPRD to the proportion reported by the National Joint
Registry (NJR)13 by means of the χ2 statistic for inde-
pendent samples (p<0.05). Second, we compared the
characteristics of the different user groups (NOACs,
LMWHs and aspirin) to patients without identiﬁed drug
use by means of the χ2 or t test statistic (p<0.05). We
used SAS 9.3 software for statistical testing and random-
isation. This study protocol was approved by the
Independent Scientiﬁc Advisory Committee (ISAC),
protocol number: 14_026R.
RESULTS
A total of 22 231 TKR patients and 25 898 THR patients
were included in our study. From all patients (n=6324)
Figure 1 Study flowchart. TKR, total knee replacement; THR, total hip replacement; NOAC, new oral anticoagulant; LMWH,
low-molecular weight heparin.
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with a positive hit for antithrombotic drug use, 600
patients were randomly selected for anonymisation of
the free-text surrounding a keyword. However, 14
patients did not give consent for this analysis. The
remaining 586 patients were further analysed to deter-
mine actual drug use (ﬁgure 1). On an average, TKR
patients were younger than THR patients. They also had
a higher BMI and used more drugs, such as statins, non-
steroidal anti-inﬂammatory drugs (NSAIDs), and antihy-
pertensives (table 1).
PPVs of drugs used for thromboprophylaxis related to
TJR ranged between 97% and 99% for NOAC and
LMWH use, and between 97% and 99% for aspirin use.
Overall, 96.2% of the hits were true positives and 3.8%
of the hits were false positives. By combining exposure
according to positive anonymised free text hits with
exposure according to product codes identiﬁcation of
drug use was increased by 57% compared to product
codes only. Ultimately, drug use was identiﬁed in a total
proportion of 18.5% of all THR and 18.6% of all TKR
surgeries. Antithrombotic drug use was determined by
free-text analysis only in 65–70% of the LMWHs group
and >80% of the NOACs group; which threefold to ﬁve-
fold increased the detection rates of these drugs com-
pared to detection by product codes. In the aspirin
group, drug use was mostly (∼90%) determined by
coded prescription data (ﬁgure 2 or see online supple-
mentary appendix table S3). Use of NOACs was higher
with our method in CPRD as compared to the NJR
reports in both THR and TKR patients when ratio of
NOAC and LMWH use was compared. NOAC/LMWH
ratio was only statistically signiﬁcantly different in TKR
patients in 2009 and 2010. All other groups were not
statistically signiﬁcantly different (table 2). Given the
lower PPV and the substantial difference of baseline
characteristics, and the limited role of thromboprophy-
laxis as related to TJR, we did not further focus on com-
paring our aspirin data with those from the NJR.
Table 3 shows that TKR and THR patients using NOACs
or LMWHs were largely similar with regard to distribution
by age, sex, comorbidities and drug use as compared to
patients with unknown drug use. Aspirin users, however,
were different as compared to unknown users particularly
with regard to a history of ischaemic heart disease.
Compared to unknown use, prescription of antithrombo-
tic drugs was higher in the highest socioeconomic status
(SES) quintile and lower in the lowest SES quintile
(except for THR patients using NOACs). Compared to
unknown users, all other groups showed a different distri-
bution across the four major regions. Moreover, only one
NOAC prescription was identiﬁed in Northern Ireland.
Furthermore, THR patients using NOACs or LMWHs had
a higher BMI as compared to unknown users.
DISCUSSION
We have developed a useful method to identify exposure
to NOACs or LMWHs related to TJR surgery. Our search
method identiﬁed NOAC and LMWH use with PPVs
between 97% and 99%. Aspirin use yielded PPVs
ranging from 91% to 95%. When combining our anon-
ymised free text method with a traditional method using
CPRD product codes, the identiﬁcation of drug use
increased by 57% on average. Moreover, the identiﬁca-
tion of NOAC use showed a ﬁvefold increase and the
Table 1 Baseline characteristics of TJR cases at date of
surgery from January 2008 to October 2012
TKR
(n=22 231)
THR
(n=25 898)
n (%) n (%)
Females 12 576 (56.6) 16 036 (61.9)
Age (years, (SD)) 68.9 (9.9) 70.1 (12.3)
18–49 years 637 (2.9) 1491 (5.8)
50–69 years 10 665 (48.0) 10 036 (38.8)
≥70 years 10 929 (49.2) 14 371 (55.5)
Socioeconomic status
Low 3519 (15.8) 4214 (16.3)
Low-medium 3581 (16.1) 4158 (16.1)
Medium 2810 (12.6) 3143 (12.1)
Medium-high 2170 (9.8) 2295 (8.9)
High 1481 (6.7) 1561 (6.0)
Missing 8670 (39.0) 10 527 (40.6)
Region
England 17 371 (78.1) 19 746 (76.2)
Northern-Ireland 480 (2.2) 795 (3.1)
Scotland 2016 (9.1) 2944 (11.4)
Wales 2364 (10.6) 2413 (9.3)
BMI, most recent before TJR
BMI (kg/m2, mean(SD)) 30.0 (5.4) 27.4 (5.2)
History of comorbidity ever before TJR
Angina pectoris 2068 (9.3) 2214 (8.5)
AMI 871 (3.9) 1190 (4.6)
Haemorrhagic stroke 110 (0.5) 177 (0.7)
Ischaemic stroke 174 (0.8) 324 (1.3)
Heart failure 581 (2.6) 885 (3.4)
Cancer 1352 (6.1) 1838 (7.1)
IBD* 320 (1.4) 315 (1.2)
Varicose veins 3744 (16.8) 3957 (15.3)
GI-ulcer 1068 (4.8) 1174 (4.5)
Atrial fibrillation 985 (4.4) 1441 (5.6)
VTE 1074 (4.8) 1183 (4.6)
History of drug use within 6 months before TJR
Statins 8471 (38.1) 8293 (32.0)
Systemic
glucocorticoids
1227 (5.5) 1413 (5.5)
Any NSAID 8708 (39.2) 9027 (34.9)
COX-2 selective
NSAIDs
685 (3.1) 663 (2.6)
Non-selective
NSAIDs
8148 (36.7) 8506 (32.8)
Antibiotics 6764 (30.4) 7587 (29.3)
Antihypertensives 12 948 (58.2) 13 553 (52.3)
*IBD: Crohn’s disease and ulcerative colitis.
AMI, acute myocardial infarction; BMI, body mass index; GI,
gastrointestinal; IBD, inflammatory bowel disease; NSAID,
non-steroidal anti-inflammatory drug; THR, total hip replacement;
TJR, total joint replacement; TKR, total knee replacement; VTE,
venous thromboembolic event.
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exposure to LMWHs a more than threefold increase
as compared to identiﬁcation by product codes. Users of
NOACs or LMWHs were largely similar to patients with
unknown tromboprophylaxis related to TJR surgery with
regards to age, sex, comorbidities and use of other
drugs. As expected, aspirin users were different and had,
for example, more often a history of ischaemic heart
disease.
To our knowledge, anonymised free text has only
been used once to identify antithrombotic drug use in
the CPRD.10 However, details of the electronic search
method used in this study are unclear and results were
restricted to rivaroxaban use only. In this paper, we
present an effective and highly efﬁcient approach to
additionally identify exposure to multiple antithrombotic
drug classes, using a predeﬁned set of keywords. Positive
hits using the selected keywords in anonymised free-text
notes were highly associated with actual use, especially
the use of NOAC and LMWH. Thus, we believe that our
free-text search method is a valid method for the add-
itional identiﬁcation of drug use in the CPRD. When
combining our anonymised free text method with a trad-
itional method using CPRD product codes, identiﬁca-
tion of drug use is increased by 57% compared to the
identiﬁcation based on product codes. This increase of
NOAC identiﬁcation is somewhat higher than the three-
fold increase of rivaroxaban use presented by Martinez
et al.10 This difference could be caused by an overesti-
mation in our method due to false positive responses.
However, previously described PPVs indicate this can
only account for 1–3% overestimation. It could also be
due to the fact that we determined both rivaroxaban
and dabigatran use, whereas Martinez and colleagues
only measured rivaroxaban use. An alternative explan-
ation is that Martinez et al underestimated the drug util-
isation. Our method could be more sensitive due to the
wider variety of keywords used in our electronic search.
While we found a method to increase the detection rate
of drug use, the question that arises is whether there is a
reason why drug use was identiﬁed in these speciﬁc
patients (ie, are these patients different compared to the
patients without identiﬁed drug use, and could this differ-
ence be the reason why drug use was identiﬁed in the
former group and not in the latter). In order to determine
whether we were dealing with a deviating group of patients
and to conﬁrm external validity, we ﬁrst compared use of
NOACs and LMWHs with annual NJR reports. We did not
include aspirin use in this analysis because of expected dif-
ferences based on the fact that aspirin is indicated for
various other cardiovascular diseases. The ratio of NOAC
and LMWH use in our CPRD analysis appeared to be dif-
ferent compared to the NJR reports in TKR patients in
2009 and 2010 only. This could be due to the fact that
NOAC prescription is considered to be new and therefore
more likely to be mentioned in the free-text notes as com-
pared to LMWH use. To further investigate this, we also
compared comorbidities and history of drug use of
NOACs, LMWHs or aspirin among patients with unknown
drug exposure status.
Only minor differences in characteristics were found
between NOAC or LMWH users and patients with an
unknown exposure status associated with TJR surgery
(table 3). This suggests that these groups are comparable
Table 2 Difference in NOAC/LMWH ratio found in the CPRD and the NJR
TKR THR
Year Source NOAC (%) LMWH (%) Ratio p Value NOAC (%) LMWH (%) Ratio p Value
2008 CPRD 3.7 96.3 0.04 0.56 3.1 96.9 0.03 0.29
NJR 2.3 97.7 0.02 1.0 99.0 0.01
2009 CPRD 22.7 77.4 0.29 0.01 17.5 82.5 0.21 0.10
NJR 9.5 90.6 0.10 9.5 90.5 0.10
2010 CPRD 37.4 62.6 0.60 0.02 33.2 66.8 0.50 0.11
NJR 22.7 77.3 0.29 22.9 77.1 0.30
2011 CPRD 36.5 63.6 0.57 0.07 30.7 69.3 0.44 0.39
NJR 24.6 75.4 0.33 25.2 74.8 0.34
CPRD, Clinical Practice Research Datalink; LMWH, low-molecular weight heparins; NJR, National Joint Registry; NOAC, new oral
anticoagulants; THR, total hip replacement; TKR, total knee replacement.
Figure 2 Drug use according to identification method. TKR,
total knee replacement; THR, total hip replacement; NOAC,
new oral anticoagulant; LMWH, low-molecular weight heparin.
Nielen JTH, et al. BMJ Open 2015;5:e009017. doi:10.1136/bmjopen-2015-009017 5
Open Access
group.bmj.com on March 15, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
Table 3 Characteristics of user groups identified by free-text analysis and product codes after total joint replacement
TKR (n=22 231) n (%) THR (n=25 898) n (%)
NOAC n=450
LMWH
n=1164
Aspirin
n=2519
Unknown
n=18 098
NOAC
n=488
LMWH
n=1534
Aspirin
n=2770
Unknown
n=21 106
Females 268 (59.6) 659 (56.6) 1281 (50.9)* 10 368 (57.3) 287 (58.8) 943 (61.5) 1602 (57.8)* 13 204 (62.6)
Age (years, (SD)) 68.5 (9.0) 69.0 (9.5) 71.8 (8.7)* 68.5 (10.0) 68.2 (10.7)* 69.5 (11.4) 73.7 (10.9)* 69.7 (12.5)
Socioeconomic status
Low 75 (16.7)* 169 (14.5)* 305 (12.1)* 2970 (16.4) 78 (16.0) 244 (15.9)* 344 (12.4)* 3548 (16.8)
Low-medium 81 (18.0)* 191 (16.4)* 381 (15.1)* 2928 (16.2) 81 (16.6) 263 (17.1)* 377 (13.6)* 3437 (16.3)
Medium 64 (14.2)* 179 (15.4)* 280 (11.1)* 2287 (12.6) 54 (11.1) 226 (14.7)* 316 (11.4)* 2547 (12.1)
Medium-high 29 (6.4)* 106 (9.1)* 232 (9.2)* 1803 (10.0) 42 (8.6) 150 (9.8)* 231 (8.3)* 1872 (8.9)
High 39 (8.7)* 114 (9.8)* 171 (6.8)* 1157 (6.4) 31 (6.4) 142 (9.3)* 160 (5.8)* 1228 (5.8)
Missing 162 (36.0)* 405 (34.8)* 1150 (45.7)* 6953 (38.4) 202 (41.4) 509 (33.2)* 1342 (48.4)* 8474 (40.1)
Region
England 388 (86.2)* 963 (82.7)* 1735 (68.9)* 14 285 (78.9) 386 (79.1)* 1267 (82.6)* 1795 (64.8)* 16 298 (77.2)
Northern-Ireland 0 (0.0)* 43 (3.7)* 145 (5.8)* 292 (1.6) 1 (0.2)* 56 (3.7)* 242 (8.7)* 496 (2.4)
Scotland 42 (9.3)* 83 (7.1)* 313 (12.9)* 1565 (8.6) 60 (12.3)* 137 (8.9)* 405 (14.6)* 2342 (11.1)
Wales 20 (4.4)* 75 (6.4)* 326 (12.4)* 1956 (10.8) 41 (8.4)* 74 (4.8)* 328 (11.8)* 1970 (9.3)
BMI, most recent before TJR
BMI (kg/m2, mean(SD)) 30.0 (5.5) 30.2 (5.5) 29.9 (5.2) 30.0 (5.4) 28.4 (5.4)* 27.8 (5.3)* 27.6 (5.3)* 27.4 (5.2)
History of comorbidity ever before TJR
Angina pectoris 33 (7.3) 110 (9.5)* 611 (24.3)* 1314 (7.3) 34 (7.0) 112 (7.3) 628 (22.7)* 1440 (6.8)
AMI 9 (2.0) 62 (5.3)* 269 (10.7)* 531 (2.9) 20 (4.1) 65 (4.2) 358 (12.9)* 747 (3.5)
Haemorrhagic stroke 6 (1.3)* 7 (0.6) 10 (0.4) 87 (0.5) 2 (0.4) 13 (0.8) 15 (0.5) 147 (0.7)
Ischaemic stroke 2 (0.4)* 6 (0.5) 56 (2.2)* 110 (0.6) 0 (0.0)* 21 (1.4) 80 (2.9)* 223 (1.1)
Heart failure 8 (1.8) 36 (3.1) 110 (4.4)* 427 (2.4) 10 (2.0) 53 (3.5) 167 (6.0)* 655 (3.1)
Cancer 29 (6.4) 77 (6.6) 176 (7.0)* 1070 (5.9) 32 (6.6) 111 (7.2) 204 (7.4) 1491 (7.1)
IBD† 8 (1.8) 22 (1.9) 44 (1.7) 246 (1.4) 11 (2.3)* 17 (1.1) 38 (1.4) 249 (1.2)
Varicose veins 75 (16.7) 215 (18.5) 449 (17.8) 3005 (16.6) 79 (16.2) 252 (16.4) 440 (15.9) 3186 (15.1)
GI-ulcer 23 (5.1) 75 (6.4)* 136 (5.4) 834 (4.6) 20 (4.1) 70 (4.6) 149 (5.4)* 935 (4.4)
Atrial fibrillation 9 (2.0)* 84 (7.2)* 137 (5.4)* 755 (4.2) 20 (4.1) 116 (7.6)* 237 (8.6)* 1068 (5.1)
VTE 26 (5.8) 96 (8.2)* 113 (4.5) 839 (4.6) 12 (2.5)* 119 (7.8)* 122 (4.4) 930 (4.4)
History of drug use within 6 months before TJR
Statins 172 (38.2) 482 (41.4)* 1644 (65.3)* 6173 (34.1) 168 (34.4)* 515 (33.6)* 1639 (59.2)* 5971 (28.3)
Systemic glucocorticoids 25 (5.6) 76 (6.5) 124 (4.9) 1002 (5.5) 26 (5.3) 86 (5.6) 150 (5.4) 1151 (5.5)
Any NSAID 171 (38.0) 450 (38.7) 867 (34.4)* 7220 (39.9) 190 (38.9) 569 (37.1) 837 (30.2)* 7431 (35.2)
COX-2 selective
NSAIDs
20 (4.4) 41 (3.5) 62 (2.5) 562 (3.1) 11 (2.3) 42 (2.7) 65 (2.3) 545 (2.6)
Non-selective NSAIDs 153 (34.0) 419 (36.0) 818 (32.5)* 6758 (37.3) 182 (37.3) 543 (35.4) 784 (28.3)* 6997 (33.2)
Antibiotics 145 (32.2) 394 (33.8)* 770 (30.6) 5455 (30.1) 133 (27.3) 481 (31.4)* 968 (34.9)* 6005 (28.5)
Antihypertensives 261 (58.0) 704 (60.5)* 1972 (78.3)* 10 011 (55.3) 259 (53.1) 803 (52.3)* 2036 (73.5)* 10 455 (49.5)
Percentages may not add up to 100% due to rounding.
*Statistically significant difference as compared to patients with unknown exposure with regard to chemical thromboprophylaxis (p<0.05). THR patients using NOACs, LMWHs, or aspirin were
compared to THR patients with unknown exposure. TKR patients using NOACs, LMWHs, or aspirin were compared to TKR patients with unknown exposure.
†IBD: Crohn’s disease and ulcerative colitis.
AMI, acute myocardial infarction; BMI, body mass index; GI, gastrointestinal; IBD, inflammatory bowel disease; NSAID, non-steroidal anti-inflammatory drug; THR, total hip replacement; TJR,
total joint replacement; TKR, total knee replacement; VTE, venous thromboembolic event.
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and that there is no apparent reason for a detection bias
of NOAC or LMWH use in these speciﬁc patients. This is
reassuring when long-term effects and side effects of the
different drugs are compared in further research. As
expected, aspirin users were very different compared to
unknown users with regard to comorbidities and drug
use (table 3). This is most likely due to the fact that
aspirin is indicated for multiple other conditions such as
angina pectoris, the prevention of myocardial infarction
and other types of ischaemic heart disease. Therefore,
our method seems to have limited usability for the identi-
ﬁcation of aspirin use in chemical thromboprophylaxis
related to TJR. Differences in drug use according to
region may be caused by use of regional guidelines.
NICE guidance is predominantly designed for use in
England and Wales. The Health and Social Care (HSC)
and the Scottish Intercollegiate Guidelines Network
(SIGN) are responsible for guidance in Northern Ireland
(NI) and Scotland, respectively. However, linkage with
NICE guidelines for implementation in NI has been avail-
able since 2006.
Our study had various strengths. To the best of our
knowledge, this is the ﬁrst study reporting an effective
method to identify antithrombotic drug use from anon-
ymised free text in a large population-based GP database
in a peer-reviewed scientiﬁc journal. Moreover, our
method can be implemented at relatively low costs, since
actual anonymisation of free text is not required. This will
then allow us to use the wealth of data in the world’s
largest primary care database to study, for example, the
potential side effects of thromboprophylaxis associated
with TJR. Our study also had limitations. We were practic-
ally unable to calculate false or true negatives. As a result,
we were unable to determine the speciﬁcity and sensitivity
of our method. In order to evaluate whether documenta-
tion of the exposure was differential between patients with
a positive hit and patients without a hit, we applied two
methods. First, we assessed distribution of NOAC and
LMWH use from an external source, the National Joint
Registration (NJR). Second, we assessed differences in
baseline characteristics of the various exposure groups to
the group without a hit. With these surrogate measure-
ments we have generated information concerning the
potential differential detection of drug use exposure.
Another limitation was that we were able to identify throm-
boprophylaxis related to TJR for only 18% of our patients,
whereas actual thromboprophylaxis is likely to be close to
100%. This is probably the result of under-reporting of
thromboprophylaxis by either hospitals, the GP or simply
because discharge letters were sent to GPs as scanned PDF
ﬁles rather than searchable free text. Nevertheless, we
were still able to substantially increase identiﬁcation using
anonymised free text compared to identiﬁcation based on
product codes only. In the future, this may be further
enhanced by linking to other data sources such as the
inhospital prescribing data, or by making the existing
linkage between the NJR and CPRD available to research-
ers without any restrictions.
In conclusion, we have developed a useful method to
identify exposure to NOACs or LMWHs associated with
TJR surgery. We can conclude that positive hits using the
selected keywords in anonymised free-text notes are
strongly associated with actual use and that by using this
method, identiﬁcation of drug use has increased ﬁve-
fold. Furthermore, identiﬁed users of NOACs and
LMWH users appear to be reasonably similar to patients
without identiﬁed drug use (table 3). In contrast, aspirin
users were very different as compared to patients
without identiﬁed drug use, possibly due to the fact that
aspirin is prescribed for various other health problems.
Identiﬁcation of drugs used for a speciﬁc postsurgery
health ailment can be substantially enhanced by using
our method; similar methods may be used for the identi-
ﬁcation of drugs prescribed for other diseases or
hospital-speciﬁc medications such as biologicals and
blood products. Our method is a useful tool to identify
exposure to NOACs or LMWHs related to total TKR or
THR surgery in the CPRD, and increases statistical
power to evaluate potential side effects of these drugs in
pharmacoepidemiological studies.
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